Download PDF
Exp Clin Endocrinol Diabetes 2020; 128(10): 693-698
DOI: 10.1055/a-0950-9892
Article

Single Centre Experience in Patients with Primary Hyperparathyroidism: Sporadic, Lithium-associated and in Multiple Endocrine Neoplasia

Sabine Dillenberger   *
1   Centre for Endocrinology, Diabetology & Osteology, Philipp’s University Marburg, Marburg, Germany
,
Detlef K. Bartsch
2   Department of Visceral-, Thoracic- and Vascular Surgery, Philipp’s University Marburg, Marburg, Germany
,
Elisabeth Maurer
2   Department of Visceral-, Thoracic- and Vascular Surgery, Philipp’s University Marburg, Marburg, Germany
,
Peter Herbert Kann
1   Centre for Endocrinology, Diabetology & Osteology, Philipp’s University Marburg, Marburg, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Purpose It is assumed that primary hyperparathyroidism (pHPT) in Multiple Endocrine Neoplasia (MEN) and lithium-associated pHPT (LIHPT) are associated with multiple gland disease (MGD), persistence and recurrence. The studies purpose was to determine frequencies, clinical presentation and outcome of sporadic pHPT (spHPT), LIHPT and pHPT in MEN. Additional main outcome measures were the rates of MGD and persistence/recurrence.

Methods Retrospective analysis of medical records of 682 patients with pHPT who had attended the University Hospital of Marburg between 01–01–2004 and 30–06–2013. All patients were sent a questionnaire asking about their history of lithium medication.

Results Out of 682 patients, 557 underwent primary surgery (532 spHPT, 5 LIHPT, 20 MEN), 38 redo-surgery (31 spHPT, 7 MEN), 55 were in follow-up due to previous surgery (16 spHPT, 1 LIHPT, 38 MEN) and 37 were not operated (33 spHPT, 1 LIHPT, 3 MEN). Primary surgeries were successful in 97.4%, revealed singular adenomas in 92.4%, double adenomas in 2.9% and MGD in 3.4% of the cases. Rates of MGD in MEN1 (82.35%) were significantly higher than in spHPT (3.8%), while there was no significant difference between LIHPT (20%) and spHPT. Rates of persistence/recurrence did not significantly differ due to type of surgery (bilateral/unilateral) or type of HPT (spHPT/LIHPT/MEN).

Conclusions History of lithium medication is rare among pHPT patients. While MGD is common in MEN1, rates of MGD, persistence or recurrence in LIHPT were not significantly higher than in spHPT.

Key words

hyperparathyroidism - lithium - multiple endocrine neoplasia, multiple gland disease - outcome

* Current Address: Sabine Dillenberger, Department of Pediatrics, University Clinic of Münster, Albert-Schweitzer-Campus 1, 48149 Münster.




Publication History

Received: 17 November 2018
Received: 17 May 2019

Accepted: 05 June 2019

Article published online:
14 August 2019

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Zahrani AA, Levine MA. Primary hyperparathyroidism. Lancet 1997; 349: 1233-1238
    CrossrefPubMedGoogle Scholar
  • 2 Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 2036-2040
    CrossrefPubMedGoogle Scholar
  • 3 Dotzenrath C, Kaetsch AK, Pfingsten H. et al. Neuropsychiatric and cognitive changes after surgery for primary hyperparathyroidism. World J Surg 2006; 30: 680-685
    CrossrefPubMedGoogle Scholar
  • 4 Delorme S, Hoffner S. Diagnostik des Hyperparathyreoidismus. Radiologe 2003; 43: 275-283
    CrossrefPubMedGoogle Scholar
  • 5 Twigt BA, Scholten A, Valk GD. et al. Differences between sporadic and MEN related primary hyperparathyroidism: Clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J Rare Dis 2013; 8: 50
    CrossrefPubMedGoogle Scholar
  • 6 Hannan FM, Nesbit MA, Christie PT. et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab 2008; 4: 53-58
    CrossrefPubMedGoogle Scholar
  • 7 Ruda JM, Hollenbeak CS, Stack BC. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132: 359-372
    CrossrefPubMedGoogle Scholar
  • 8 Iacobone M, Carnaille B, Palazzo FF. et al. Hereditary hyperparathyroidism-A consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 2015; 400: 867-886
    CrossrefPubMedGoogle Scholar
  • 9 Phay JE, Moley FM, Laimore TC. Multiple endocrine neoplasias. Semin Surg Oncol 2000; 18: 324-332
    CrossrefPubMedGoogle Scholar
  • 10 Fyrsten E, Norlen O, Hessman O. et al. Long-term surveillance of treated hyperparathyroidism for multiple endocrine neoplasia type 1: Recurrence or hypoparathyroidism?. World J Surg 2015; 40: 615-662
    CrossrefPubMedGoogle Scholar
  • 11 Garfinkel PE, Ezrin C, Stancer HC. Hypothyroidism and hyperparathyroidism associated with lithium. Lancet 1973; 2: 331-332
    CrossrefPubMedGoogle Scholar
  • 12 Meehan AD, Humble MB, Yazarloo P. et al. The prevalence of lithium-associated hyperparathyroidism in a large Swedish population attending psychiatric outpatient units. J Clin Psychopharmacol 2015; 35: 279-285
    CrossrefPubMedGoogle Scholar
  • 13 Gitlin M. Lithium side effects and toxicity: Prevalence and management strategies. Int J Bipolar Disord 2016; 4: 27
    CrossrefPubMedGoogle Scholar
  • 14 Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: Report of four cases and review of the literature. Eur J Endocrinol 2009; 160: 317-323
    CrossrefPubMedGoogle Scholar
  • 15 Brown EM. Lithium induces abnormal calcium-regulated PTH release in dispersed bovine parathyroid cells. J Clin Endocrinol Metab 1981; 52: 1046-1048
    CrossrefPubMedGoogle Scholar
  • 16 Haden ST, Stoll AL, McCormick S. et al. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997; 82: 2844-2848
    CrossrefPubMedGoogle Scholar
  • 17 Komatsu M, Shimizu H, Tsuruta T. et al. Effect of lithium on serum calcium level and parathyroid function in manic-depressive patients. Endocr J 1995; 42: 691-695
    CrossrefPubMedGoogle Scholar
  • 18 Mak TW, Shek CC, Chow CC. et al. Effects of lithium therapy on bone mineral metabolism: A two-year prospective longitudinal study. J Clin Endocrinol Metab 1998; 83: 3857-3859
    PubMedGoogle Scholar
  • 19 Birnbaum J, Klandorf H, Giuliano A. et al. Lithium stimulates the release of human parathyroid hormone in vitro. J Clin Endocrinol Metab 1988; 66: 1187-1191
    CrossrefPubMedGoogle Scholar
  • 20 Hundley JC, Woodrum DT, Saunders BD. et al. Revisiting lithium-associated hyperparathyroidism in the era of intraoperative parathyroid hormone monitoring. Surgery 2005; 138: 1027-1031
    CrossrefPubMedGoogle Scholar
  • 21 Järhult J, Ander S, Asking B. et al. Long-term results of surgery for lithium-associated hyperparathyroidism. Br J Surg 2010; 97: 1680-1685
    CrossrefPubMedGoogle Scholar
  • 22 Skandarajah AR, Palazzo FF, Henry JF. Lithium-associated hyperparathyroidism: Surgical strategies in the era of minimally invasive parathyroidectomy. World J Surg 2011; 35: 2432-2439
    CrossrefPubMedGoogle Scholar
  • 23 Norlen O, Sidhu S, Sywak M. et al. Long-term outcome after parathyroidectomy for lithium-induced hyperparathyroidism. Br J Surg 2014; 101: 1252-1256
    CrossrefPubMedGoogle Scholar
  • 24 Meehan AD, Udumyan R, Kardell M. et al. Lithium-associated hypercalcemia: Pathophysiology, prevalence, management. World J Surg 2018; 42: 415-424
    CrossrefPubMedGoogle Scholar
  • 25 Awad SS, Miskulin J, Thompson N. Parathyroid adenomas vs. four-gland hyperplasia as the cause of primary hyperparathyroidism in patients with prolonged lithium therapy. World J Surg 2003; 27: 486-488
    CrossrefPubMedGoogle Scholar
  • 26 Carchman E, Ogilvie J, Holst J. et al. Appropriate surgical treatment of lithium-associated hyperparathyroidism. World J Surg 2008; 32: 2195-2199
    CrossrefPubMedGoogle Scholar
  • 27 Marti JL, Yang CS, Carling T. et al. Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Ann Surg Oncol 2012; 19: 3465-3471
    CrossrefPubMedGoogle Scholar
  • 28 Livingstone C, Rampes H. Lithium: A review of its metabolic adverse effects. J Psychopharmacol 2006; 20: 347-355
    CrossrefPubMedGoogle Scholar
  • 29 Ballehaninna UK, Nguyen SM, Chamberlain RS. Lithium associated hyperparathyroidism: An evidence based surgical approach. Surgical. Science 2011; 2: 468-475
    PubMedGoogle Scholar
  • 30 Kallner G, Petterson U. Renal, thyroid and parathyroid function during lithium treatment: Laboratory tests in 207 people treated for 1–30 years. Acta Psychiatr Scand 1995; 91: 48-51
    CrossrefPubMedGoogle Scholar
  • 31 Abdullah H, Bliss R, Guinea AI. et al. Pathology and outcome of surgical treatment for lithium-associated hyperparathyroidism. Br J Surg 1999; 86: 91-93
    CrossrefPubMedGoogle Scholar
  • 32 Sneider MS, Solorzano CC, Montano RE. et al. Sporadic primary hyperparathyroidism in young individuals: Different disease and treatment?. J Surg Res 2009; 155: 100-103
    CrossrefPubMedGoogle Scholar
  • 33 Irvin GL, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg 2004; 239: 704-711
    CrossrefPubMedGoogle Scholar
  • 34 Udelsman R. Six Hundred Fifty-Six Consecutive Explorations for Primary Hyperparathyroidism. Ann Surg 2002; 235: 665-672
    CrossrefPubMedGoogle Scholar
  • 35 Karakas E, Schneider R, Rothmund M. et al. Initial surgery for benign primary hyperparathyroidism: An analysis of 1 300 patients in a teaching hospital. World J Surg 2014; 38: 2011-2018
    CrossrefPubMedGoogle Scholar
  • 36 Thakker RV. Multiple endocrine neoplasia-syndromes of the twentieth century. J Clin Endocrinol Metab 1998; 83: 2617-2620
    CrossrefPubMedGoogle Scholar